Learn, Analyse & Invest
only with

+91

Download Orca

To access realtime data for Reliance Industries Ltd, and use advance features for tradingRegisterorLogin to Orca.

Jubilant Pharmova Ltd.

Jubilant Pharmova

₹ 0.00

0.00 (0.00)%

NSE

BSE

Healthcare

Small-cap - With a market cap of ₹179.82 Cr.

EX-Date	Purpose
04 06 2021	Final Dividend & Audited Results
23 07 2021	Quarterly Results
22 10 2021	Quarterly Results
04 02 2022	Quarterly Results
27 05 2022	Final Dividend & Audited Results
02 08 2022	Quarterly Results
21 10 2022	Quarterly Results
03 02 2023	Quarterly Results
29 05 2023	Final Dividend & Audited Results
19 07 2023	Quarterly Results
27 10 2023	Quarterly Results
02 02 2024	Quarterly Results
25 10 2024	Quarterly Results
31 01 2025	Quarterly Results
16 05 2025	Audited Results & Final Dividend
29 07 2025	Quarterly Results
31 10 2025	Quarterly Results

News

01-FEB-2023

Jubilant Pharmova’s arm receives USFDA’s approval for Technetium Mertiatide Injection

This approval is effective from January 30, 2023

09:47 AM

02-AUG-2025

USFDA concludes PAI at Jubilant Pharmova’s arm’s facility at Roorkee

The USFDA has issued 4 observations pursuant to the completion of audit

04:10 PM

02-SEP-2025

Jubilant Pharmova completes transfer of API business to Jubilant Biosys

The company had received approval from board of directors of the company on June 12, 2025 for the same

11:58 AM

03-AUG-2022

USFDA completes audit at Jubilant Pharmova’s step down subsidiary’s facility

The USFDA has issued six observations pursuant to the completion of the audit

11:14 AM

03-FEB-2023

Jubilant Pharmova reports consolidated net loss of Rs 16 crore in Q3FY23

Total consolidated income of the company increased by 18.65% to Rs 1561.98 crore for Q3FY23

03:59 PM

03-FEB-2024

USFDA concludes audit at Jubilant Pharmova’s step down subsidiary’s solid dosage formulations facility

The USFDA has issued 4 observations pursuant to the completion of audit

11:58 AM

05-NOV-2025

Jubilant Pharmova’s arm gets 9 observations for Canada facility after USFDA audit

JHSGP will submit an action plan on the observations

03:15 PM

08-MAR-2023

USFDA classifies Jubilant Pharmova’s API Facility as VAI

USFDA had inspected its API manufacturing facility at Nanjangud during December 05, 2022 to December 13, 2022

03:58 PM

10-OCT-2025

Jubilant Pharmova’s arm launches New Sterile Fill & Finish line at facility in US

The launch plays a key role in Jubilant HollisterStier’s multi-phase expansion strategy and brings an additional 50% capacity at its Spokane manufacturing facility

02:41 PM

11-NOV-2023

Jubilant Pharmova’s arm receives USFDA’s approval for Technetium Sulfur Colloid Injection

For this approval, Jubilant is eligible for 180 days of exclusivity through the ‘Competitive Generic Therapy’ designation from the USFDA

10:32 AM

13-JUN-2025

Jubilant Pharmova gets nod to sell, transfer API business to Jubilant Biosys

The board of directors of the company in their meeting held on June 12, 2025 has approved the same

12:21 PM

13-MAR-2025

Jubilant Pharmova’s arm gets EIR with VAI status for Maryland facility

With the receipt of the EIR from the USFDA, the inspection stands successfully closed

10:59 AM

14-DEC-2022

USFDA concludes inspection at Jubilant Pharmova’s API manufacturing facility in Nanjangud

The US FDA has issued eight observations pursuant to the completion of the inspection

03:30 PM

14-JUL-2022

Jubilant Pharmova’s arm enters into loan agreement with Standard Chartered Bank

The agreement is for five year loan facility for repayment of existing term loan and bonds aggregating $350 million

09:22 AM

17-JAN-2025

USFDA completes inspection at Jubilant Pharmova’s arm’s solid oral formulations facility at Salisbury

USFDA has issued five observations with no repeat observations

09:22 AM

17-MAR-2023

Jubilant Pharmova’s arm gets additional loan facility from Government of Canada

This expansion project is aimed at upgrading the company’s Montreal facility

04:49 PM

19-JUL-2023

Jubilant Pharmova reports 87% fall in Q1 consolidated net profit

Total consolidated income of the company increased by 9.06% at Rs 1595.50 crore for Q1FY24

03:22 PM

20-MAR-2025

Jubilant Pharmova’s arm inks Shareholders’ Agreement with Pierre Fabre SA

The name of JASMIN has been changed to ‘Jubilant Biosys France’ which is now a subsidiary of JBIRSPL

02:59 PM

22-SEP-2025

USFDA completes PADE inspection of Jubilant Pharmova’s arm

The inspection closed with no observations

10:23 AM

27-JAN-2025

Jubilant Pharmova’s arm voluntary pays $25 million term loan

The company has prepaid $25 million term loan on January 24, 2025

10:11 AM